{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:07:44Z","timestamp":1788444464451,"version":"build-2803163510"},"reference-count":29,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100001219","name":"Lymphoma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"Memorial Sloan-Kettering Cancer Center","doi-asserted-by":"publisher","award":["P30\u20105P30CA008748\u201055"],"award-info":[{"award-number":["P30\u20105P30CA008748\u201055"]}],"id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"Memorial Sloan-Kettering Cancer Center","doi-asserted-by":"publisher","award":["P50\u20105P50CA192937\u201005"],"award-info":[{"award-number":["P50\u20105P50CA192937\u201005"]}],"id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K08CA270202\u201001"],"award-info":[{"award-number":["K08CA270202\u201001"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017239","name":"BeiGene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017239","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016282","name":"MEI Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016282","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    The combination of the phosphatidylinositol 3\u2010kinase delta (PI3K\u03b4) inhibitor zandelisib with the Bruton's tyrosine kinase (BTK) inhibitor zanubrutinib was hypothesized to be synergistic and prevent resistance to single\u2010agent therapy. This phase 1 study (NCT02914938) included a dose\u2010finding stage in patients with relapsed\/refractory (R\/R) B\u2010cell malignancies (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200920) and disease\u2010specific expansion cohorts in follicular lymphoma (FL;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200931) or mantle cell lymphoma (MCL;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200919). The recommended phase 2 dose was zandelisib 60\u2009mg on Days 1\u20137 plus zanubrutinib 80\u2009mg twice daily continuously in 28\u2010day cycle. In the total population, the most common adverse events (AEs; all grades\/grade 3\u20134) were neutropenia (35%\/24%), diarrhoea (33%\/2%), thrombocytopenia (32%\/8%), anaemia (27%\/8%), increased creatinine (25%\/0%), contusion (21%\/0%), fatigue (21%\/2%), nausea (21%\/2%) and increased aspartate aminotransferase (24%\/6%). Three patients discontinued due to AEs. The overall response rate was 87% (complete response [CR]\u2009=\u200933%) for FL and 74% (CR\u2009=\u200947%) for MCL. The median duration of response and progression\u2010free survival (PFS) were not reached in either group. The estimated 1\u2010year PFS was 72.3% (95% confidence interval [CI], 51.9\u201385.1) for FL and 56.3% (95% CI, 28.9\u201376.7) for MCL (median follow\u2010up: 16.5 and 10.9\u2009months respectively). Zandelisib plus zanubrutinib was associated with high response rates and no increased toxicity compared to either agent alone.\n                  <\/jats:p>","DOI":"10.1111\/bjh.19419","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T03:53:50Z","timestamp":1710820430000},"page":"1762-1770","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas"],"prefix":"10.1111","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3062-6819","authenticated-orcid":false,"given":"Jacob D.","family":"Soumerai","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital Cancer Center  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1116-3246","authenticated-orcid":false,"given":"Catherine S.","family":"Diefenbach","sequence":"additional","affiliation":[{"name":"Perlmutter Cancer Center at NYU Langone Health  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Jagadeesh","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Cleveland Clinic  Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Asch","sequence":"additional","affiliation":[{"name":"Stephenson Cancer Center University of Oklahoma Health Sciences Center  Oklahoma City Oklahoma USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijeet","family":"Kumar","sequence":"additional","affiliation":[{"name":"University of Arizona  Tucson Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela L.","family":"Tsai","sequence":"additional","affiliation":[{"name":"Swedish Cancer Institute  Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Jandl","sequence":"additional","affiliation":[{"name":"Stony Brook University Hospital  Stony Brook New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9346-9013","authenticated-orcid":false,"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center University of Miami School of Medicine  Miami Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishalee P.","family":"Kenkre","sequence":"additional","affiliation":[{"name":"Carbone Cancer Center University of Wisconsin  Madison Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1813-9812","authenticated-orcid":false,"given":"Farrukh","family":"Awan","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Novotny","sequence":"additional","affiliation":[{"name":"BeiGene, LTD  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Huang","sequence":"additional","affiliation":[{"name":"BeiGene, LTD  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Miao","sequence":"additional","affiliation":[{"name":"MEI Pharma, Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhu","family":"Rajagopalan","sequence":"additional","affiliation":[{"name":"PR Consulting  Mountain Lakes New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Ghalie","sequence":"additional","affiliation":[{"name":"MEI Pharma, Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Zelenetz","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,3,19]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.07.029"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1402"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-386417"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90114-0"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.93"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.6.2695"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.316"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001685"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0650"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171221"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006555"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2183"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-019-00668-y"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00333-3"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7511"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00687"},{"key":"e_1_2_9_18_1","first-page":"152","article-title":"Safety and activity of the highly specific BTK inhibitor BGB\u20103111 in patients with indolent and aggressive non Hodgkin's lymphoma","volume":"130","author":"Tam CS","year":"2017","journal-title":"Blood"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3703"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004074"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006083"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001160"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-619163"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.7519"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30196-0"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3504"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01108-x"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014162"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00200-5"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.19419","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T03:43:27Z","timestamp":1730691807000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.19419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,19]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1111\/bjh.19419"],"URL":"https:\/\/doi.org\/10.1111\/bjh.19419","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,19]]},"assertion":[{"value":"2024-01-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}